Anti-c antibodies can cause pregnancy loss, though this outcome is uncommon. These antibodies form when a pregnant person’s immune system encounters fetal red blood cells carrying the “little c” antigen, a protein on the surface of red blood cells that the mother’s body doesn’t recognize. In serious cases, the antibodies attack fetal red blood cells and cause severe anemia, which can lead to hydrops fetalis (dangerous fluid buildup in the fetus) and, if untreated, stillbirth or miscarriage. The good news is that most anti-c pregnancies don’t reach that point, and effective monitoring tools exist to catch problems early.
How Anti-c Antibodies Affect a Pregnancy
When your body encounters blood cells with an unfamiliar protein, it mounts an immune response. The first antibodies produced are a type that can’t cross the placenta, so they don’t reach the fetus. The problem begins when your immune system shifts to producing a different class of antibody (IgG) that does cross the placenta freely. Once these antibodies reach the fetal bloodstream, they latch onto the baby’s red blood cells and mark them for destruction.
This process is called hemolytic disease of the fetus and newborn, or HDFN. As fetal red blood cells are destroyed faster than the baby can replace them, anemia sets in. Mild anemia may cause no symptoms at all. Severe anemia forces the fetal heart to work harder to deliver oxygen, and fluid can accumulate in the baby’s tissues and organs. This condition, hydrops fetalis, is the most dangerous stage. Survival rates for hydropic fetuses are significantly lower, around 61%, compared to about 96% for those without hydrops.
How Common Is Severe Disease?
Anti-c is considered one of the more clinically significant Rh antibodies after anti-D (the antibody behind “Rh disease”). It has real potential to cause HDFN, but the overall prevalence of c-related alloimmunization is low, ranging from roughly 9 to 185 per 100,000 pregnancies across different studies. Among affected pregnancies in one series, only about 7% of fetuses required treatment after birth. So while the antibody is capable of causing serious harm, most pregnancies with anti-c antibodies result in healthy outcomes, either because the baby doesn’t carry the c antigen or because the immune response stays mild.
What Determines Your Risk Level
Two factors matter most: whether the baby carries the c antigen and how high your antibody levels climb.
If the biological father doesn’t carry the c antigen, the baby won’t either, and the antibodies have nothing to target. Genetic testing of the father can clarify this. If the father carries one copy of the gene, there’s roughly a 50% chance the baby inherits it. If the father carries two copies, the baby will definitely have the antigen. In some cases, cell-free fetal DNA testing from a maternal blood draw can determine the baby’s antigen status directly.
Antibody titer levels are the other key piece. Titers measure the concentration of anti-c antibodies in your blood. Research has identified a titer of 1:32 or greater as the threshold that flags serious risk. In one study, a titer at or above 1:32, or the presence of hydrops on ultrasound, identified all fetuses with serious hemolytic disease. Below that level, the risk of severe anemia is much lower, though titers are typically rechecked every few weeks to watch for rising levels.
How Fetal Anemia Is Detected
The standard tool for monitoring at-risk pregnancies is a specialized Doppler ultrasound that measures how fast blood flows through an artery in the baby’s brain, called the middle cerebral artery. When a fetus is anemic, its blood becomes thinner and flows faster. This measurement can detect moderate or severe anemia with 100% sensitivity and a false positive rate of only 12%. It’s completely noninvasive, requiring no needle and no risk to the pregnancy.
This replaced older methods that required taking a sample of amniotic fluid, which carried a small risk of worsening the immune response or causing complications. With Doppler monitoring, your care team can track the baby’s condition through regular ultrasound appointments, typically every one to two weeks once titers reach concerning levels. The velocity measurements are adjusted for gestational age, so the test works reliably throughout the second and third trimesters.
Treatment When Anemia Becomes Severe
If Doppler measurements indicate the baby is developing significant anemia, intrauterine transfusion is the primary treatment. This procedure delivers compatible red blood cells directly to the fetus, correcting the anemia before it progresses to hydrops. Overall fetal survival rates with intrauterine transfusion are around 90%, and neonatal survival among those born alive reaches nearly 99%.
Outcomes are substantially better when transfusion happens before hydrops develops. Fetuses that already have fluid buildup at the time of their first transfusion have survival rates closer to 61%, compared to over 95% for those treated earlier. This is exactly why regular monitoring matters: catching a downward trend in the baby’s blood counts before it becomes critical gives the best chance of a healthy outcome. Some babies need only one transfusion, while others may need several over the course of the pregnancy depending on how quickly the antibodies continue to destroy red blood cells.
Research comparing outcomes across different antibody types (anti-D, other Rh antibodies including anti-c, and anti-M) has found no significant difference in fetal or neonatal outcomes when intrauterine transfusion is used. In other words, anti-c pregnancies that receive appropriate treatment do just as well as those complicated by anti-D.
Why the First Affected Pregnancy Is Rarely the Worst
Sensitization to the c antigen usually happens during a previous pregnancy or after a blood transfusion. During a first sensitized pregnancy, the immune response is often still building, and antibody levels may stay below dangerous thresholds. The real risk escalates in subsequent pregnancies. Each time your immune system encounters the c antigen again, it responds faster and more aggressively. This is why titer monitoring becomes especially important in second and later pregnancies after anti-c antibodies have been identified.
If you’ve been told you have anti-c antibodies, the most important thing is that your pregnancy is managed by a team experienced with red cell alloimmunization. With proper titer monitoring, Doppler surveillance, and timely intervention when needed, the vast majority of these pregnancies end with a healthy baby.